Overview

To quantify the diagnostic, prognostic and therapeutic value of spectrometric analysis of exhaled breath from hematological patients with respiratory infection.

Eligibility

Inclusion Criteria:

• Age ≥ 18y at start of study
• One of the following diagnoses:
  • De novo, refractory or relapsed AML/MDS receiving intensive chemotherapy
  • De novo, refractory or relapsed ALL/T-lymphoblastic lymphoma receiving intensive chemotherapy
  • Aplastic anemia requiring ATG therapy
  • Any patient admitted for either autologous hematopoietic stem cell transplantation. Transplantation may not have been performed at time of enrolment.
  • Any patient admitted with allogeneic hematopoietic stem cell transplantation within the last year, or planned during this admission.
• Written informed consent obtained from the patient

Exclusion Criteria:

• Hematological disease beyond the specified inclusion criteria
• Signs of active respiratory infection
• If previously enrolled: incomplete clearance of all signs of respiratory infection (both clinically, microbiologically and radiologically).